Making the Leap from IV to Subcutaneous, with Halozyme's ENHANZE® Technology
Sponsored by
Halozyme, Inc.*
Finn Doyle, Halozyme, discusses how Halozyme's ENHANZE® technology enables the shift from IV to SC, the impacts of doing so, and the keys to successful drug delivery collaborations.
How can therapeutics like biologics and small molecule drugs evolve in their delivery? Finn Doyle, SVP and General Manager of ENHANZE® at Halozyme, sits down to discuss exactly how these innovative therapeutics can be delivered subcutaneously where they have previously only been administered via IV, the impacts of doing so, and the keys to successful drug delivery collaborations.
Key Takeaways:
- How switching to a subcutaneous delivery model impacts patients, healthcare providers and drug development companies
- Keys to successful partnerships and collaborations
- How Halozyme's ENHANZE® technology enables the shift from IV to SC
To learn more about the PODD Conference, please visit PODDConference.com.
Sponsored By:
